ArticleVaccines2020
Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models.
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 47 citations in OpenAlex.
- Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.Emerging microbes & infections · 2025Trial
- Modulating Chikungunya and Mayaro virus-induced disease severity in mice using low concentrations of anti-IFNAR1 antibodies.Emerging microbes & infections · 2026Article
- Ross River virus transmission, infection, and disease: two and a half decades of research progress-an updated cross-disciplinary review.Clinical microbiology reviews · 2026Review
- In Silico Characterization of Conserved Epitopes in Alphavirus E2 Proteins: A Promising Approach for Pan-vaccine Design.ACS omega · 2025Article
- Rhesus macaques model human Mayaro virus disease and transmit to Aedes aegypti mosquitoes.PLoS neglected tropical diseases · 2025Article
- Development of a virulent O'nyong'nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine.PLoS neglected tropical diseases · 2025Article
- Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes.PLoS pathogens · 2025Article
- Evolution of Zika virus inVirus evolution · 2025Article
- Insect-specific virus platforms for arbovirus vaccine development.Frontiers in immunology · 2025Review
- Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses.PLoS pathogens · 2024Article
- Generating prophylactic immunity against arboviruses in vertebrates and invertebrates.Nature reviews. Immunology · 2024Review
- Article
- Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge.NPJ vaccines · 2024Article
- Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance.bioRxiv : the preprint server for biology · 2024Article
- Development and application of a colloidal-gold immunochromatographic strip for detecting Getah virus antibodies.Applied microbiology and biotechnology · 2024Article
- Characterisation of a Japanese Encephalitis virus genotype 4 isolate from the 2022 Australian outbreak.Npj viruses · 2024Article
- Research trends on alphavirus receptors: a bibliometric analysis.Frontiers in cellular and infection microbiology · 2024Review
- Mayaro virus pathogenesis and immunity in rhesus macaques.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 2 countries.
Funding
Abstract
Chikungunya virus (CHIKV), Ross River virus (RRV), o'nyong nyong virus (ONNV), Mayaro virus (MAYV) and Getah virus (GETV) represent arthritogenic alphaviruses belonging to the Semliki Forest virus antigenic complex. Antibodies raised against one of these viruses can cross-react with other serogroup members, suggesting that, for instance, a CHIKV vaccine (deemed commercially viable) might provide cross-protection against antigenically related alphaviruses. Herein we use human alphavirus isolates (including a new human RRV isolate) and wild-type mice to explore whether infection with one virus leads to cross-protection against viremia after challenge with other members of the antigenic complex. Persistently infected Rag1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.